Shopping Cart 0
Cart Subtotal
USD 0

Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company's pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Sosei's NVA237 is a long acting bronchodilator for the treatment of chronic obstructive pulmonary disease. It also discovers and develops pharmaceutical products targeting G protein-coupled receptors. The company provides treatment for Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. It operates through its office located in London, the UK. Sosei is headquartered in Tokyo, Japan.

Sosei Group Corp (4565)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Sosei Group Corp, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

Heptares Therapeutics Raises USD 21 Million In Series B Financing 15

Partnerships 16

Heptares Therapeutics Enters into Research Agreement with Imperial College London 16

Heptares Therapeutics Enters into Research Agreement with Juntendo University 17

Heptares Therapeutics and PeptiDream Enter into Agreement 18

Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 19

Heptares Therapeutics Enters into Research Agreement with University of Cambridge 20

Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 21

Jitsubo Enters into Agreement with Heptares Therapeutics 22

Heptares Therapeutics and leadXpro Enter into Agreement 23

Heptares Therapeutics to Form Partnership with Kymab 24

Heptares Therapeutics Enters into Agreement with Pfizer 25

MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 26

Sosei Plans to Enter into Agreement with Novartis 27

Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 28

MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 29

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 30

Heptares Therapeutics Extends Collaboration with the UK Medical Research 31

ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 32

Licensing Agreements 33

Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 33

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 34

AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35

Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36

Equity Offering 37

Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37

Sosei Group Raises USD33 Million in Private Placement of Shares 38

Sosei Group to Raise USD7 Million in Private Placement of Shares 39

Sosei Group to Raise USD66 Million in Public Offering of Shares 40

Jitsubo to Raise USD1.7 Million in Private Placement 41

Sosei Announces Private Placement Of Preference Shares For USD 3.9 Million 42

Asset Transactions 43

Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43

Acquisition 44

Formosa Labs Acquires Activus Pharma from Sosei Group 44

Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45

Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47

Sosei Acquires Heptares Therapeutics for USD400 Million 48

Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49

Sosei Group Corp-Key Competitors 50

Sosei Group Corp-Key Employees 51

Sosei Group Corp-Locations And Subsidiaries 52

Head Office 52

Other Locations & Subsidiaries 52

Recent Developments 54

Financial Announcements 54

Nov 09, 2017: Sosei Group: Consolidated Financial Results for the Second Period FY2017 (IFRS) 54

Corporate Communications 58

Jun 04, 2018: Sosei Announces Appointment of Chris Cargill as Interim CFO 58

Jan 19, 2018: Sosei Group Announces Resignation Of Fiona Marshall As Chief Scientific Officer 59

Jan 19, 2018: Changes in Executive Management at Sosei 60

Product News 61

May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 61

Other Significant Developments 62

Feb 02, 2018: Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts 62

Jan 26, 2017: Achievement of sales milestone for COPD products 63

Appendix 64

Methodology 64

About GlobalData 64

Contact Us 64

Disclaimer 64


List Of Figure

List of Figures

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Sosei Group Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Sosei Group Corp, Deals By Therapy Area, 2012 to YTD 2018 10

Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Heptares Therapeutics Raises USD 21 Million In Series B Financing 15

Heptares Therapeutics Enters into Research Agreement with Imperial College London 16

Heptares Therapeutics Enters into Research Agreement with Juntendo University 17

Heptares Therapeutics and PeptiDream Enter into Agreement 18

Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 19

Heptares Therapeutics Enters into Research Agreement with University of Cambridge 20

Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 21

Jitsubo Enters into Agreement with Heptares Therapeutics 22

Heptares Therapeutics and leadXpro Enter into Agreement 23

Heptares Therapeutics to Form Partnership with Kymab 24

Heptares Therapeutics Enters into Agreement with Pfizer 25

MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 26

Sosei Plans to Enter into Agreement with Novartis 27

Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 28

MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 29

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 30

Heptares Therapeutics Extends Collaboration with the UK Medical Research 31

ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 32

Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 33

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 34

AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35

Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36

Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37

Sosei Group Raises USD33 Million in Private Placement of Shares 38

Sosei Group to Raise USD7 Million in Private Placement of Shares 39

Sosei Group to Raise USD66 Million in Public Offering of Shares 40

Jitsubo to Raise USD1.7 Million in Private Placement 41

Sosei Announces Private Placement Of Preference Shares For USD 3.9 Million 42

Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43

Formosa Labs Acquires Activus Pharma from Sosei Group 44

Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45

Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47

Sosei Acquires Heptares Therapeutics for USD400 Million 48

Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49

Sosei Group Corp, Key Competitors 50

Sosei Group Corp, Key Employees 51

Sosei Group Corp, Other Locations 52

Sosei Group Corp, Subsidiaries 52

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Sosei Group Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company's pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Sosei's NVA237 is a long acting bronchodilator for the treatment of chronic obstructive pulmonary disease. It also discovers and develops pharmaceutical products targeting G protein-coupled receptors. The company provides treatment for Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. It operates through its office located in London, the UK. Sosei is headquartered in Tokyo, Japan.

Sosei Group Corp (4565)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Sosei Group Corp, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

Heptares Therapeutics Raises USD 21 Million In Series B Financing 15

Partnerships 16

Heptares Therapeutics Enters into Research Agreement with Imperial College London 16

Heptares Therapeutics Enters into Research Agreement with Juntendo University 17

Heptares Therapeutics and PeptiDream Enter into Agreement 18

Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 19

Heptares Therapeutics Enters into Research Agreement with University of Cambridge 20

Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 21

Jitsubo Enters into Agreement with Heptares Therapeutics 22

Heptares Therapeutics and leadXpro Enter into Agreement 23

Heptares Therapeutics to Form Partnership with Kymab 24

Heptares Therapeutics Enters into Agreement with Pfizer 25

MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 26

Sosei Plans to Enter into Agreement with Novartis 27

Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 28

MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 29

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 30

Heptares Therapeutics Extends Collaboration with the UK Medical Research 31

ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 32

Licensing Agreements 33

Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 33

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 34

AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35

Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36

Equity Offering 37

Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37

Sosei Group Raises USD33 Million in Private Placement of Shares 38

Sosei Group to Raise USD7 Million in Private Placement of Shares 39

Sosei Group to Raise USD66 Million in Public Offering of Shares 40

Jitsubo to Raise USD1.7 Million in Private Placement 41

Sosei Announces Private Placement Of Preference Shares For USD 3.9 Million 42

Asset Transactions 43

Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43

Acquisition 44

Formosa Labs Acquires Activus Pharma from Sosei Group 44

Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45

Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47

Sosei Acquires Heptares Therapeutics for USD400 Million 48

Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49

Sosei Group Corp-Key Competitors 50

Sosei Group Corp-Key Employees 51

Sosei Group Corp-Locations And Subsidiaries 52

Head Office 52

Other Locations & Subsidiaries 52

Recent Developments 54

Financial Announcements 54

Nov 09, 2017: Sosei Group: Consolidated Financial Results for the Second Period FY2017 (IFRS) 54

Corporate Communications 58

Jun 04, 2018: Sosei Announces Appointment of Chris Cargill as Interim CFO 58

Jan 19, 2018: Sosei Group Announces Resignation Of Fiona Marshall As Chief Scientific Officer 59

Jan 19, 2018: Changes in Executive Management at Sosei 60

Product News 61

May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 61

Other Significant Developments 62

Feb 02, 2018: Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts 62

Jan 26, 2017: Achievement of sales milestone for COPD products 63

Appendix 64

Methodology 64

About GlobalData 64

Contact Us 64

Disclaimer 64


List Of Figure

List of Figures

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Sosei Group Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Sosei Group Corp, Deals By Therapy Area, 2012 to YTD 2018 10

Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 12

Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Heptares Therapeutics Raises USD 21 Million In Series B Financing 15

Heptares Therapeutics Enters into Research Agreement with Imperial College London 16

Heptares Therapeutics Enters into Research Agreement with Juntendo University 17

Heptares Therapeutics and PeptiDream Enter into Agreement 18

Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 19

Heptares Therapeutics Enters into Research Agreement with University of Cambridge 20

Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 21

Jitsubo Enters into Agreement with Heptares Therapeutics 22

Heptares Therapeutics and leadXpro Enter into Agreement 23

Heptares Therapeutics to Form Partnership with Kymab 24

Heptares Therapeutics Enters into Agreement with Pfizer 25

MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 26

Sosei Plans to Enter into Agreement with Novartis 27

Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 28

MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 29

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 30

Heptares Therapeutics Extends Collaboration with the UK Medical Research 31

ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 32

Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 33

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 34

AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35

Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36

Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37

Sosei Group Raises USD33 Million in Private Placement of Shares 38

Sosei Group to Raise USD7 Million in Private Placement of Shares 39

Sosei Group to Raise USD66 Million in Public Offering of Shares 40

Jitsubo to Raise USD1.7 Million in Private Placement 41

Sosei Announces Private Placement Of Preference Shares For USD 3.9 Million 42

Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43

Formosa Labs Acquires Activus Pharma from Sosei Group 44

Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45

Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47

Sosei Acquires Heptares Therapeutics for USD400 Million 48

Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49

Sosei Group Corp, Key Competitors 50

Sosei Group Corp, Key Employees 51

Sosei Group Corp, Other Locations 52

Sosei Group Corp, Subsidiaries 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Sosei Group Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.